Skip to main content
Clinical Trials/JPRN-UMIN000048296
JPRN-UMIN000048296
Recruiting
未知

Phase II clinical trial to evaluate the safety and efficacy of particle radiotherapy preceded atezolizumab plus bevacizumab treatment in patients with unresectable multiple hepatocellular carcinoma - Phase II clinical trial to evaluate the safety and efficacy of particle radiotherapy preceded atezolizumab plus bevacizumab treatment in patients with unresectable multiple hepatocellular carcinoma

Kobe University0 sites43 target enrollmentSeptember 1, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Hepatocellular carcinoma
Sponsor
Kobe University
Enrollment
43
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 1, 2022
End Date
October 31, 2027
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients with multiple cancers. Patients with multiple cancers, but no signs of recurrence for at least 5 years after completion of treatment, and patients with epithelial cancer or endoscopically resectable gastrointestinal cancer within 5 years of completion of treatment may be enrolled. 2\.Patients with untreated or poorly treated esophageal and/or gastric varices with or at high risk of bleeding. Patients who have undergone esophagogastroduodenoscopy prior to enrollment and who have been evaluated and treated for all varices, large or small, according to the institution's standard of care, and who are judged to have a low risk of bleeding may be enrolled. 3\. Patients who are judged to be inappropriate to participate in this study by the principal investigator or sub\-investigator. 4\. Patients who are judged to be inappropriate according to the latest practice guideline for the use of atezolizumab/bevacizumab combination therapy. 5\. Other patients deemed inappropriate by the study investigators

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Trial to evaluate the safety and efficacy of a research drug in combination with antiretroviral treatment to cure people infected with HIV-1 without antiretroviral treatment.
EUCTR2018-000497-30-ESFundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)12
Active, not recruiting
Not Applicable
Clinical phase II trial to evaluate the safety and efficacy of clofarabine and treosulfan conditioning prior to peripheral blood stem cells transplantation in paediatric and adult patients with advanced haematological malignancies - NDpatients affected by advanced haematological malignanciesMedDRA version: 9.1Level: HLGTClassification code 10018865Term: Haematopoietic neoplasms (excl leukaemias and lymphomas)
EUCTR2008-006972-31-ITOSPEDALE S. RAFFAELE
Active, not recruiting
Phase 1
Clinical phase II trial to evaluate the safety and efficacy of treosulfan based conditioning prior to allogenic haematopoietic stem cell transplantation in patients with haematological malignancies. - ND
EUCTR2005-005182-11-ITOSPEDALE S. RAFFAELE
Active, not recruiting
Phase 1
Clinical phase II trial to evaluate the safety and efficacyof treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly patients withAcute Myeloid Leukemia or Myelodysplastic Syndrome. - NDelderly patients withAcute Myeloid Leukemia or Myelodysplastic SyndromeMedDRA version: 9.1Level: HLTClassification code 10024291Term: Leukaemias acute myeloid
EUCTR2008-000664-16-ITOSPEDALE S. RAFFAELE15
Active, not recruiting
Phase 1
Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery.
CTIS2024-515235-29-00Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud15